| INTRODUCTION
Oral squamous cell carcinoma (OSCC), one of the 10 most prevalent cancers worldwide, has a global annual incidence of approximately 300 000 new cases and 145 000 deaths, with considerable geographic and environmental risk factor differences. 1 Although the overall incidence of OSCC has been decreasing in some areas of the world, which is consistent with decreases in tobacco use, the global incidence of oral cavity cancers is predicted to rise in the next 20 years because of demographic changes. 2 Clinical features including tumor size and cervical lymph node metastasis are the most consisting prognostic factors for OSCC, but it frequently shows unpredictable prognosis. Among the histological characteristics, depth of invasion has shown prognostic importance for OSCC, 3 leading to its incorporation in the T-stage classification in the new edition of the stating manual of the American Joint Cancer
Committee. 4 However, OSCC still shows significant morbidity and decades. 5 Therefore, better prognostic markers are required to better understand and select more aggressive tumors.
Rho-associated coiled-coil kinase 2 (ROCK2) is an oncoprotein with important roles in tumor proliferation, apoptosis, adhesion, migration, and invasion, and its deregulated expression has been reported in tumor cells from hepatocellular carcinomas, 6 pancreatic adenocarcinomas, 7 colorectal cancers, 8 gastric cancers, 9 breast carcinomas, 10 esophageal cancers, 11 renal cell carcinomas, 12 and oral cancer. 13 In most of those studies, overexpression of ROCK2 has been related to tumor progression, metastasis, and poor clinical outcome, 7, [9] [10] [11] [12] and its inhibition suppresses tumor invasion in vitro. 8 ROCK2 expression is also observed in the tumor microenvironment cells, including inflammatory cells, endothelial cells, and cancer-associated fibroblasts (CAF). 14, 15 In CAF, expression of ROCK2 is predicted to stimulate Rho kinase signaling pathway, which in turn may contribute to tumor cell survival, proliferation, and tumor progression. 14 In OSCC, CAF have been associated with poor outcome and promotion of tumorigenesis in vitro. 16, 17 Owing to this pivotal function in cancer, ROCK2 has been suggested as a promising therapeutic target, but there are no data on the prognostic value for OSCC.
On this context, we have evaluated the prognostic role of ROCK2 expression and its association with CAF density in a cohort of
OSCCs from Brazil and Finland.
| MATERIALS AND METHODS
This study was carried out following the REMARK guidelines for tumor marker prognostic studies. 
| Immunohistochemistry
Immunohistochemistry was performed on 3-lm sections. Slides were dewaxed in xylene and rehydrated using a graded alcohol series.
Endogenous peroxidase activity was blocked with a 3% hydrogen 
| Statistical analysis
Associations between immunohistochemical expression of ROCK2
and clinicopathological parameters of the tumors were performed using cross-tabulation and Chi-squared test. Survival curves were constructed based on the Kaplan-Meier method and compared with the log-rank test. For multivariate survival analysis, the Cox proportional hazard model with a stepwise method was employed.
The level of significance considered was 5% (P ≤ .05).
| RESULTS
Of 93 Table S1 .
Eleven (11.8%) cases were negative for ROCK2. The expression of ROCK2 was localized in both nucleus and cytoplasm of the tumor cells, showing variable distribution and intensity ( Figure 1 ).
Immunopositivity was also observed in some inflammatory and fibroblast-like cells within the stroma (Fig. S1 ). Regarding the cytoplasmatic ROCK2 immunoreactivity, 24 (25.8%) samples were classified as low expression and 69 (74.2%) as high expression.
High expression of ROCK2 was significantly associated with male gender (P = .006), drinking habit (P = .01), high clinical stage (.002), and abundant CAF density in the stroma (P = .002) ( Table 1) . No significant differences were found between ROCK2 expression and smoking habit, tumor site, treatment, histological grade, margin status, and recurrence (Table 1) . We also determined whether the presence of CAF was associated with clinicopathological features of OSCC patients. As depicted in Table S2 , a high intensity of CAF was significantly associated with tumor site (P = .03) and poorly differentiated tumors (P = .001). A positive but moderate correlation between ROCK2 expression and CAF density was observed in the Spearman test (r = .52, P = .002).
Univariate survival analysis based on log-rank test revealed a significant association of age, clinical stage of the tumor, CAF density and ROCK2 expression with DSS, and of age and CAF density with DFS (Table 2) . Patients with high expression of ROCK2 had shorter DSS compared with patients with low ROCK2 expression (Fig. S2 ).
High ROCK2 expression was associated with a 5-year DSS of 42.9% compared with 70.3% for patients with low ROCK2 immunoreactivity (P = .04). Multivariate Cox proportional hazard regression model analysis was built to further evaluate the impact of ROCK2 expression on DSS and DFS (Table 3) . In this analysis, ROCK2 did not withstand as an independent prognostic factor, but age and clinical stage remained as independent prognostic factor for DSS, whereas age and CAF density were pointed out as prognostic parameters of DFS in this cohort. Rho-associated coiled-coil kinase 2 belongs to the serine-threonine kinase AGC family and is a downstream intracellular messenger following small GTPase RhoA activity. 19 With the description that ROCK2 controls cytoskeleton organization by regulating actin filaments, 20 many studies have investigated its roles in cancer, revealing the participation in a wide range of processes related to tumorigenesis in vitro such as proliferation, apoptosis, adhesion, migration, and invasion. In consonance, ROCK inhibition due to synthetic drugs/peptides or microRNAs was found to suppress tumor growth and metastasis in vivo. [6] [7] [8] In a recent study, Vennin et al 21 showed that priming with Fasudil, a specific ROCK inhibitor, disrupts the extracellular matrix scaffold, improving the treatment effectiveness in a mouse model of pancreatic cancer. Together, those results suggest that ROCK2 might be a molecular target for preventing cancer progression and metastasis.
The increased ROCK2 expression has been reported in association with metastasis and shorter survival of cancer patients. For example, in pancreatic cancers, ROCK2 levels rose with increasing tumor stage (advanced tumors showed significantly higher levels than early stage and even normal pancreatic tissue), and the survival of patients with genomic amplification or significantly elevated mRNA was significantly shorter than that in patients without ROCK2 alterations. 7 Based only on univariate Kaplan-Meier analysis, patients with colorectal cancers and high ROCK2 expression had significantly shorter survival rates than patients whose tumors showed low ROCK2 expression. 8 Our results are in line with those previous ones regarding associations with advanced clinical stage of tumors and shortened survival. Furthermore, the only published study evaluating ROCK2 in oral cancer demonstrated that in highly metastatic oral tongue SCC cells, enhanced expression of ROCK2, due to a reduction in miR-138 levels, increases the activity of Rho GTPase signaling cascade, which promotes cell migration and invasion. 13 Thus, little has been uncovered regarding the biological mechanisms related to ROCK2 in oral cancer, but our results preliminarily reveal an association with clinical outcome.
Another interesting finding of the present study relies on the CAF analysis. We recently performed a systematic review and meta-analysis to verify the value of CAF in OSCC, and demonstrated that the high presence of CAF is frequently associated with parameters that worsen the prognosis, including advanced disease stage, recurrence, tumor grade, depth of invasion, vascular, lymphatic and neural invasion, and extranodal metastatic spread, and most important, the high presence of CAF significantly predicted shortened time to disease relapse and an overall decrease in survival. 22 The protumorigenic effects of CAF are related to the vast repertoire of secreted molecules, which can directly influence the behavior of cancer cells, stimulating proliferation, invasion, and metastasis. Some of the known molecules secreted by CAF include the stromal derived factor 1 (SDF-1/CXCL12), 23 activin A and matrix metalloproteases, 17 some types of collagen and other extracellular matrix proteins such as fibronectin, 24 and ROCK2. | 125 more invasion-permissive microenvironment, facilitating tumor progression and metastasis.
In this study, the expression of ROCK2 was significantly more common in males and drinkers. Interestingly, ROCK2 was identified as a downstream effector of androgen/androgen receptor pathway, affecting migration and invasion of pancreatic cancer cells through the transcription of miR-135a, 25 and inducing endothelial cell migration. 26 In addition, ROCK2 expression was significantly elevated in ethanol-induced gastric ulcer in mice. 27 Even though the association between those predictors and ROCK2 expression is not widely addressed in the current literature, our results with OSCC clinical samples corroborate with those previous findings.
Besides the predictable associations of clinical stage with DSS and CAF density with DFS, we also found a significant association of age with both DSS and DFS at univariate and multivariate analyses. Those results are in line with previous studies that showed a worse survival in elderly patients with OSCC than in young patients. 3, 28 An important feature in favor of a causal effect of advanced age on survival is that previous studies have reported frequent comorbidities in the cardiovascular, gastrointestinal, and respiratory systems in elderly people, and demonstrated a significant impact on the prognosis of patients with oral cancer. 29, 30 Thus, those results suggest that age may affect the survival of patients with oral cancer due to the comorbid illnesses.
In closing, the expression of ROCK2 in OSCC is associated with advanced clinical stage of the tumor and poor survival, which indicates that ROCK2 may be involved in OSCC progression. Although ROCK2 may not be an independent prognostic factor, it should be further verified by prospective studies and more comprehensive follow-up.
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